BACKGROUND: Numerous studies have demonstrated elevated kappa free light chains (KFLCs) in CSF of multiple sclerosis (MS) patients. However, so far only small cohorts have been examined, and generally only through qualitative KFLCs analysis. Using a recently developed free light chain (FLC) immunoassay, it is now possible to quantitatively measure KFLCs by automated nephelometry. Our objective was to determine the extent to which KFLC levels in CSF correlated with the diagnosis of MS and CISSMS (clinically isolated syndrome suggestive of MS) compared to oligoclonal banding (OCB) and the immunoglobulin G (IgG) index. METHODS: CSF and serum samples from 438 unselected patients, including a MS group of 70 patients (41 MS, 29 CISSMS), were analysed using nephelometry and isoelectric focusing. We then retrospectively correlated results with patients' diagnoses. RESULTS: Of the MS group (n = 70), 67 patients had elevated KFLCs using the KFLC index (> or = 5.9), 64 patients showed OCB and 56 patients presented with an elevated IgG index (> or = 0.6). Sensitivities were 0.96 for the KFLC index, 0.91 for OCB and 0.80 for the IgG index. The specificity of the KFLC index for the MS group (0.86) was lower than that of OCB (0.92) but distinctly higher compared to the IgG index (0.77). CONCLUSION: In this study, an elevated KFLC-index represented the most sensitive and specific quantitative diagnostic parameter for MS. As it is measured by automated, routinely available laboratory methods, KFLC quantitation can provide a rapid and reproduceable indication of intrathecal immunological processes supporting current MS diagnostic criteria.
BACKGROUND: Numerous studies have demonstrated elevated kappa free light chains (KFLCs) in CSF of multiple sclerosis (MS) patients. However, so far only small cohorts have been examined, and generally only through qualitative KFLCs analysis. Using a recently developed free light chain (FLC) immunoassay, it is now possible to quantitatively measure KFLCs by automated nephelometry. Our objective was to determine the extent to which KFLC levels in CSF correlated with the diagnosis of MS and CISSMS (clinically isolated syndrome suggestive of MS) compared to oligoclonal banding (OCB) and the immunoglobulin G (IgG) index. METHODS: CSF and serum samples from 438 unselected patients, including a MS group of 70 patients (41 MS, 29 CISSMS), were analysed using nephelometry and isoelectric focusing. We then retrospectively correlated results with patients' diagnoses. RESULTS: Of the MS group (n = 70), 67 patients had elevated KFLCs using the KFLC index (> or = 5.9), 64 patients showed OCB and 56 patients presented with an elevated IgG index (> or = 0.6). Sensitivities were 0.96 for the KFLC index, 0.91 for OCB and 0.80 for the IgG index. The specificity of the KFLC index for the MS group (0.86) was lower than that of OCB (0.92) but distinctly higher compared to the IgG index (0.77). CONCLUSION: In this study, an elevated KFLC-index represented the most sensitive and specific quantitative diagnostic parameter for MS. As it is measured by automated, routinely available laboratory methods, KFLC quantitation can provide a rapid and reproduceable indication of intrathecal immunological processes supporting current MS diagnostic criteria.
Authors: L D Jacobs; R W Beck; J H Simon; R P Kinkel; C M Brownscheidle; T J Murray; N A Simonian; P J Slasor; A W Sandrock Journal: N Engl J Med Date: 2000-09-28 Impact factor: 91.245
Authors: Sophie Desplat-Jégo; Lionel Feuillet; Jean Pelletier; Dominique Bernard; André Ali Chérif; José Boucraut Journal: J Clin Immunol Date: 2005-07 Impact factor: 8.317
Authors: R A Rudick; D L Cookfair; N A Simonian; R M Ransohoff; J R Richert; L D Jacobs; R M Herndon; A M Salazar; J S Fischer; C V Granger; D E Goodkin; J H Simon; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munchsauer; K O'Reilly; R L Priore; R H Whitham Journal: J Neuroimmunol Date: 1999-01-01 Impact factor: 3.478
Authors: M Andersson; J Alvarez-Cermeño; G Bernardi; I Cogato; P Fredman; J Frederiksen; S Fredrikson; P Gallo; L M Grimaldi; M Grønning Journal: J Neurol Neurosurg Psychiatry Date: 1994-08 Impact factor: 10.154
Authors: Jerry A Katzmann; Raynell J Clark; Roshini S Abraham; Sandra Bryant; James F Lymp; Arthur R Bradwell; Robert A Kyle Journal: Clin Chem Date: 2002-09 Impact factor: 8.327
Authors: W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky Journal: Ann Neurol Date: 2001-07 Impact factor: 10.422
Authors: Marcel P Stoop; Leon Coulier; Therese Rosenling; Shanna Shi; Agnieszka M Smolinska; Lutgarde Buydens; Kirsten Ampt; Christoph Stingl; Adrie Dane; Bas Muilwijk; Ronald L Luitwieler; Peter A E Sillevis Smitt; Rogier Q Hintzen; Rainer Bischoff; Sybren S Wijmenga; Thomas Hankemeier; Alain J van Gool; Theo M Luider Journal: Mol Cell Proteomics Date: 2010-09 Impact factor: 5.911
Authors: Marcel P Stoop; Vaibhav Singh; Lennard J Dekker; Mark K Titulaer; Christoph Stingl; Peter C Burgers; Peter A E Sillevis Smitt; Rogier Q Hintzen; Theo M Luider Journal: PLoS One Date: 2010-08-27 Impact factor: 3.240
Authors: B Kaplan; S Golderman; E Ganelin-Cohen; A Miniovitch; E Korf; I Ben-Zvi; A Livneh; S Flechter Journal: Clin Exp Immunol Date: 2017-12-26 Impact factor: 4.330
Authors: Klaus Berek; Gabriel Bsteh; Michael Auer; Franziska Di Pauli; Astrid Grams; Dejan Milosavljevic; Paulina Poskaite; Christine Schnabl; Sebastian Wurth; Anne Zinganell; Thomas Berger; Janette Walde; Florian Deisenhammer; Harald Hegen Journal: Neurol Neuroimmunol Neuroinflamm Date: 2021-05-28